BR112022005044A2 - Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento - Google Patents

Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento

Info

Publication number
BR112022005044A2
BR112022005044A2 BR112022005044A BR112022005044A BR112022005044A2 BR 112022005044 A2 BR112022005044 A2 BR 112022005044A2 BR 112022005044 A BR112022005044 A BR 112022005044A BR 112022005044 A BR112022005044 A BR 112022005044A BR 112022005044 A2 BR112022005044 A2 BR 112022005044A2
Authority
BR
Brazil
Prior art keywords
peptide
antibody
pharmaceutical composition
treatment method
chimeric
Prior art date
Application number
BR112022005044A
Other languages
English (en)
Inventor
T P Kaumaya Pravin
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of BR112022005044A2 publication Critical patent/BR112022005044A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

PEPTÍDEO QUIMÉRICO, PEPTÍDEO SINTÉTICO, COMPOSIÇÃO FARMACÊUTICA, ANTICORPO, MÉTODO DE TRATAMENTO. São divulgadas composições relacionadas a peptídeos PD-L1 sintéticos, peptídeos PD-L1 quiméricos, anticorpos anti-PD-L1 e métodos de tratamento de câncer, doenças autoimunes e doença de Alzheimer usando os referidos peptídeos ou anticorpos.
BR112022005044A 2019-09-17 2020-09-17 Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento BR112022005044A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962901727P 2019-09-17 2019-09-17
PCT/US2020/051240 WO2021055583A1 (en) 2019-09-17 2020-09-17 Human anti-pd-l1 peptide vaccines and methods of their use

Publications (1)

Publication Number Publication Date
BR112022005044A2 true BR112022005044A2 (pt) 2022-07-05

Family

ID=74884372

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005044A BR112022005044A2 (pt) 2019-09-17 2020-09-17 Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento

Country Status (9)

Country Link
US (1) US20220362366A1 (pt)
EP (1) EP4031174A4 (pt)
JP (1) JP2022548283A (pt)
KR (1) KR20220065784A (pt)
CN (1) CN114630676A (pt)
AU (1) AU2020350666A1 (pt)
BR (1) BR112022005044A2 (pt)
CA (1) CA3151223A1 (pt)
WO (1) WO2021055583A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205796A2 (en) * 2022-04-21 2023-10-26 Ohio State Innovation Foundation Human ctla-4 peptide vaccines and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2918580T3 (es) * 2011-10-17 2022-07-19 Io Biotech Aps Inmunoterapia basada en PD-L1
US10221230B2 (en) * 2013-02-25 2019-03-05 Ohio State Innovation Foundation HER-1, HER-3 and IGF-1R compositions and uses thereof
CA2997912A1 (en) * 2015-09-09 2017-03-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Genetic engineering of macrophages for immunotherapy
AU2018243920A1 (en) * 2017-03-28 2019-10-31 Mayo Foundation For Medical Education And Research Human PD1 peptide vaccines and uses thereof
FR3078535B1 (fr) * 2018-03-05 2024-02-09 Peptinov Sas Composition vaccinale anti-pd-l1

Also Published As

Publication number Publication date
AU2020350666A1 (en) 2022-03-31
EP4031174A1 (en) 2022-07-27
US20220362366A1 (en) 2022-11-17
CA3151223A1 (en) 2021-03-25
EP4031174A4 (en) 2023-09-13
KR20220065784A (ko) 2022-05-20
WO2021055583A1 (en) 2021-03-25
CN114630676A (zh) 2022-06-14
JP2022548283A (ja) 2022-11-17

Similar Documents

Publication Publication Date Title
EA201991099A1 (ru) Антитела против cd73 и их применение
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
BR112018075737A2 (pt) anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra.
PE20210342A1 (es) Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
MX2022008341A (es) Anticuerpos anti-ccr8 y usos de estos.
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
MD3313884T2 (ro) Anticorpi anti-CD123 şi conjugaţi şi derivaţi ai acestora
EA202091747A1 (ru) Составы антитела b7-h4
MX2019012869A (es) Anticuerpos anti-sortilina y metodos para su uso.
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
MX2022005850A (es) Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
BR112022005044A2 (pt) Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
BR112019020386A2 (pt) vacinas de peptídeos de pd-1 humana e usos das mesmas